Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 10/20 | 0.77 |
| ▸ | EGFR | P00533 | 10/20 | 0.77 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | FLT3 | P36888 | 1/20 | 0.77 |
| ▸ | BLK | P51451 | 1/20 | 0.77 |
| ▸ | BMX | P51813 | 1/20 | 0.77 |
| ▸ | JAK3 | P52333 | 1/20 | 0.77 |
| ▸ | BTK | Q06187 | 1/20 | 0.77 |
| ▸ | ITK | Q08881 | 1/20 | 0.77 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.77 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 0.77 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.77 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.77 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.77 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371097 | 0.90 | EGFR (0.64) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL12398388 | 0.89 | EGFR (0.74) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL14915251 | 0.89 | EGFR (0.80) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL10127995 | 0.89 | EGFR (0.80) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL2040938 | 0.88 | EGFR (0.74) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL93699 | 0.87 | EGFR (1.00) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL29354966 | 0.87 | EGFR (1.00) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL29733655 | 0.87 | EGFR (1.00) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL15130588 | 0.86 | EGFR (0.85) | CTSCEGFRPTK2PLK4GAK | |
| SCHEMBL29809870 | 0.86 | EGFR (0.73) | CTSCEGFRPTK2PLK4GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079231-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | GATEKEEPER PHARMACEUTICAL, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | CTSC 597/4885EGFR 1/4885PTK2 29/4885 |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | CTSC 597/4885EGFR 1/4885PTK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.